Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | 0.00% | ||
| 3 Months | 33.12% | ||
| 6 Months | 13.89% | ||
| 1 Year | - | ||
| 3 Years | -45.77% | ||
| 5 Years | -43.84% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -12.33 | |||
ROE last 12 Months | -6.96 | |||
ROA (5Y Avg) | -12.14 | |||
ROA last 12 Months | -5.22 | |||
ROC (5Y Avg) | -31.10 | |||
ROC last 12 Months | -6.32 | |||
Return on invested Capital Q | -1.50 | |||
Return on invested Capital Y | -37.79 | |||
Assets Turnover | 0.70 | |||
Receivables Turnover | 4.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -41.00 | ||||
| 2.64 | ||||
| 2.62 | ||||
| 15.40 | ||||
| 19.40 | ||||
| 0.13 | ||||
| 4.15 | ||||
| 0.78 | ||||
| 278.68M | ||||
| Forward PE | -22.66 | |||
| PEG | -4.08 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.70 | ||||
| 2.90 | ||||
| 0.03 | ||||
| 0.07 | ||||
| - | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 65.20 | ||||
| -6.20 | ||||
| -1.60 | ||||
| -36.90 | ||||
| -7.03 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 105.44M | ||||
| 0.78 | ||||
| -9.02 | ||||
| 2.97 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2021 | -0.03 | 0.00 | 100.00 |
| Q02 2021 | -0.02 | -0.01 | 50.00 |
| Q01 2021 | -0.04 | -0.01 | 75.00 |
| Q04 2020 | -0.04 | 0.00 | 100.00 |
| Q03 2020 | -0.08 | 0.00 | 100.00 |
| Q02 2020 | -0.07 | -0.01 | 85.71 |
| Q01 2020 | -0.07 | -0.04 | 42.86 |
| Q04 2019 | -0.04 | -0.07 | -75.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.03 | 25.00 | Positive |
| 12/2021 QR | -0.05 | 0.00 | - |
| 12/2021 FY | -0.08 | 0.00 | - |
| 12/2022 FY | -0.09 | -50.00 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 0 |
| Shares Outstanding | 0 |
| Shares Float | 0 |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 0 |
| Avg. Weekly Volume | 0 |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 0 |
Castlight Health Inc. Class B (NYSE: CSLT) stock closed at 2.05 per share at the end of the most recent trading day (a 0.49% change compared to the prior day closing price) with a volume of 1.05M shares and market capitalization of 0.0000. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 440 people. Castlight Health Inc. Class B CEO is Maeve O'Meara.
The one-year performance of Castlight Health Inc. Class B stock is %, while year-to-date (YTD) performance is 33.12%. CSLT stock has a five-year performance of -43.84%. Its 52-week range is between and , which gives CSLT stock a 52-week price range ratio of %
Castlight Health Inc. Class B currently has a PE ratio of -41.00, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of 2.62, a price to cashflow ratio of 15.40, a PEG ratio of 2.32, a ROA of -5.22%, a ROC of -6.32% and a ROE of -6.96%. The company’s profit margin is -7.03%, its EBITDA margin is -1.60%, and its revenue ttm is $105.44 Million , which makes it $0.78 revenue per share.
Of the last four earnings reports from Castlight Health Inc. Class B, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Castlight Health Inc. Class B’s next earnings report date is -.
The consensus rating of Wall Street analysts for Castlight Health Inc. Class B is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Castlight Health Inc. Class B stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Castlight Health Inc. Class B has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Castlight Health Inc. Class B has a Buy technical analysis rating based on Technical Indicators (ADX : 23.12, ATR14 : 0.01, CCI20 : 35.09, Chaikin Money Flow : 1.00, MACD : 0.01, Money Flow Index : 0.00, ROC : 0.00, RSI : 71.52, STOCH (14,3) : 100.00, STOCH RSI : 0.00, UO : 97.62, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Castlight Health Inc. Class B in the last 12-months were: Eric Chan (Option Excercise at a value of $0), Eric Chan (Sold 15 368 shares of value $26 781 ), Maeve O'Meara (Option Excercise at a value of $0), Maeve O'Meara (Sold 198 984 shares of value $346 401 ), William Bondurant (Option Excercise at a value of $0), William Bondurant (Sold 44 895 shares of value $78 092 )
Castlight Health Inc. Class B
Castlight Health Inc provides a software-as-a-service platform. It is used for health benefits navigation for employees in the United States. Its platform matches employees to the resources their employers make available to them; managing a condition; and assists them to manage their benefits. The company derives its revenue from sales of cloud-based subscription service and professional services contracts. Castlight generates its geographical revenue from the United States.
CEO: Maeve O'Meara
Telephone: +1 415 829-1400
Address: 150 Spear Street, San Francisco 94105, CA, US
Number of employees: 440
